T1	SectionAnnotate 462 488	History of Present Illness
T4	SectionAnnotate 5844 5865	Past Medical History:
T5	SectionAnnotate 6274 6296	Past Surgical History:
T6	SectionSkip 6636 8650	Current Outpatient Medications   Medication Instructions    acetaminophen (TYLENOL) 325 mg, Oral, Once PRN    bisacodyL (DULCOLAX) 5 mg, Oral, Once PRN    budesonide-glycopyr-formoterol (BREZTRI AEROSPHERE) 160-9-4.8 mcg/actuation INH 2 puffs, Inhalation, 2 times daily    calcium carbonate-vitamin D (OSCAL D) 1,250 mg (500 mg elemental)-200 unit tablet 1 Tbsp, Oral, Every 4 Hours PRN    CALCIUM CITRATE ORAL 1 tablet, Oral, Daily Scheduled    capecitabine (XELODA) 500 mg tablet Take 3 tabs (1500 mg) in the morning with food, take 2 tabs (1000 mg) in the evening with food. Take for 7 days, and then do not take for 7 days.    CREON 6,000-19,000 -30,000 unit capsule TAKE 1 CAPSULE BY MOUTH 3 TIMES DAILY WITH MEALS.    denosumab (PROLIA) 60 mg, Subcutaneous, See Admin Instructions, Inject 60 mg subcutaneously as directed*****Clinic administered every 6 mos    dronabinoL (MARINOL) 2.5 mg, Oral, 2 Times Daily Before Meals Scheduled, Take 1 hour before breakfast and one hour before dinner.    famotidine (PEPCID ORAL) Oral    GLIMEPIRIDE ORAL 5 mg, Oral, Daily At Bedtime Scheduled    lipase-protease-amylase (CREON) 6,000-19,000 -30,000 unit capsule TAKE 1 CAPSULE BY MOUTH 3 TIMES DAILY WITH MEALS.    melatonin 1 mg 
 tablet Oral, Daily At Bedtime Scheduled    mirtazapine (REMERON) 15 mg tablet TAKE 1 TABLET BY MOUTH EVERYDAY AT BEDTIME    multivitamin tablet 1 tablet, Oral, Daily Scheduled, Brand:  Centrum    ondansetron (ZOFRAN) 8 mg, Oral, Every 8 Hours PRN    pantoprazole (PROTONIX) 40 mg EC tablet Take Pantoprazole 40 ***** tablets, twice daily. Pantoprazole 40 mg tablet 30 minutes before your first meal of the day and 30 minutes before bedtime.    pantoprazole (PROTONIX) 40 mg, Oral, 2 times daily    polyethylene glycol (MIRALAX) 17 g, Oral, Daily Scheduled    prochlorperazine (COMPAZINE) 10 mg, Oral, Every 6 Hours PRN    senna (SENOKOT) 17.2 mg, Oral, Daily At Bedtime Scheduled    sucralfate (CARAFATE) 1 g, Oral, 4 Times Daily Before Meals and Bedtime Scheduled
T7	SectionAnnotate 8657 8671	FAMILY HISTORY
T8	SectionAnnotate 8673 8687	Family History
T9	SectionAnnotate 8991 9018	PERSONAL AND SOCIAL HISTORY
T10	SectionAnnotate 9020 9034	Social History
T11	SectionAnnotate 9384 9408	Social History Narrative
T12	SectionSkip 9980 10137	Relevant Diagnostic Studies    Lab results   I personally reviewed and interpreted each of the patient's relevant lab tests as outlined in my Assessment/Plan
T13	SectionSkip 10141 10702	Lab Results   Component Value Date    WBC Count 8.3 01/31/2022    Abs Neutrophils 3.18 01/31/2022    Hemoglobin 9.7 (L) 01/31/2022    Hematocrit 30.8 (L) 01/31/2022    Platelet Count 241 01/31/2022    Creatinine 0.73 11/24/2021    Bilirubin, Total 0.3 11/24/2021    Alkaline Phosphatase 80 11/24/2021    AST 18 11/24/2021    Alanine transaminase 11 11/24/2021    Albumin, Serum / Plasma 3.0 (L) 11/24/2021    INR 1.1 06/01/2021    Sodium, Serum / Plasma 135 11/24/2021    Potassium, Serum / Plasma 4.0 11/24/2021    Calcium, total, Serum / Plasma 9.4 11/24/2021
T14	SectionSkip 10707 11231	Lab Results   Component Value Date    Cancer Antigen 19-9 <2 11/18/2021    Cancer Antigen 19-9 <2 10/27/2021    Cancer Antigen 19-9 <2 06/06/2021       Radiology  I personally reviewed and interpreted each of the patient's relevant imaging studies in conjunction with the corresponding formal radiology reports, as outlined in my Assessment/Plan     CT Abdomen /Pelvis with and without Contrast    CT Abdomen /Pelvis with Contrast    Result Date: 01/31/2022  CT ABDOMEN/PELVIS WITH CONTRAST  *****/*****/***** *****:***** PM
T15	SectionSkip 11390 11437	MEDICATIONS: Iohexol 350 - 100 mL - Intravenous
T16	SectionSkip 11438 13625	FINDINGS: Visualized lung bases:  For chest findings, please see the separately dictated report from the CT of the chest of the same date. Liver:  Persistent mild intrahepatic and extrahepatic biliary dilation with decreased pneumobilia. Similar position of common bile duct stent. Gallbladder: Prior cholecystectomy. Similar fluid in the gallbladder fossa. 
 Spleen:  Unremarkable Pancreas:  Similar size of ill-defined pancreatic mass in the uncinate process, measuring approximately 5.2 x 2.0 cm (series 5, image 72) compared to 5.2 x 2.2 cm on 11/18/2021. Adrenal Glands:  Unremarkable Kidneys:  Contrast in the bilateral collecting systems and ureters. Benign cyst in the right kidney lower pole. GI Tract:  Persistent encasement of the third portion of the duodenum by the pancreatic mass. Similar enhancing soft tissue within the stent, suspicious for tumor (series 5, image 76). Unchanged position of duodenal stent. Interval gastrojejunostomy with axios stent in place. Nondistended stomach. Diverticulosis without findings of acute diverticulitis. Vasculature:  Moderate atherosclerotic disease of the abdominal aorta and its branches. Unchanged obliteration of the superior mesenteric vein at the level of the pancreatic mass. The mass demonstrate similar abutment of the distal superior mesenteric artery. Lymphadenopathy: Similar mesenteric lymph nodes adjacent to the mass, the largest measuring 1.0 cm (series 5, image 68). Peritoneum: No ascites Bladder: Contrast layering dependently in the bladder. Reproductive organs: Unremarkable Bones:  No suspicious lesions Extraperitoneal soft tissues: Similar medium fat-containing left inguinal hernia. Lines/drains/medical devices: As above. RADIATION DOSE INDICATORS: Exposure Events: 3 , CTDIvol Min: 6.8 mGy, CTDIvol Max: 6.8 mGy, DLP: 449.1 mGy.cm. The following accession numbers are related to this dose report *****,*****     1.  Similar size of pancreatic mass centered in the uncinate process and invading the duodenum. Similar peripancreatic lymph nodes. 2.  Interval placement of gastrojejunal stent. No findings of proximal obstruction.     CT Chest with Contrast    Result Date: 01/31/2022  CT CHEST WITH CONTRAST
T17	SectionSkip 13968 15277	FINDINGS: Right chest wall port with tip terminating in the superior cavoatrial junction. LUNGS: Overall, slight improvement in waxing and waning multifocal peribronchovascular groundglass, now worse in the right upper lobe and improved in the left upper lobe. Bronchial wall thickening, most notably within the right lower lobe. PLEURA: No pleural effusion or pneumothorax. MEDIASTINUM: Unchanged mediastinal lymph nodes. HEART/GREAT VESSELS: The heart is normal in size without evidence of pericardial effusion. Severe coronary artery atherosclerotic calcifications. Normal caliber thoracic aorta and main pulmonary artery. BONES/SOFT TISSUES: No suspicious osseous lesions. VISIBLE ABDOMEN: Please see dedicated Abdomen and Pelvis CT report.     1.  Slight improvement in waxing and waning multifocal peribronchovascular groundglass, compatible with an organizing pneumonia pattern of lung injury, which may be secondary to infection or drug reaction. No new or enlarging solid pulmonary nodules. 2. Persistent bronchial wall thickening of the lower lobes, possibly secondary to airway spread of infection. Report dictated by: ***** ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging    CT Chest with Contrast    Result Date: 01/05/2022  CT CHEST WITH CONTRAST
T18	SectionSkip 15649 17856	FINDINGS: SUPPORT DEVICE(S): Right chest port 
 catheter terminates at the superior cavoatrial junction. LUNGS: Increased upper lobe predominant peribronchovascular groundglass/perilobular opacities. Increased atelectasis in the right middle lobe and lingula. New nodular consolidation in the left lower lobe (series 301, image 364). PLEURA: No pleural effusion. MEDIASTINUM: A few mediastinal nodes have increased in size. For reference, an AP window node measures 0.6 cm in short axis, previously 0.4 cm (series 2, image 96). These are probably reactive to regional inflammation. Mild diffuse esophageal wall thickening, nonspecific. HEART/GREAT VESSELS: Normal heart size. No pericardial effusion. Mild coronary artery calcifications. BONES/SOFT TISSUES: No suspicious lesion. VISIBLE ABDOMEN: Increased pneumobilia with intrahepatic and extra hepatic biliary ductal dilation. Thickened, enhancing walls of the hepatic, cystic, and upper common bile ducts, similar to prior exam. Partially imaged common bile duct stent. Several small vessels course along the gastric wall, as seen previously. Partially imaged gastrostomy stent communicating with a left upper quadrant bowel loop. Partially imaged stent within the more posterior lateral aspect of this same bowel loop. Mildly enlarged enhancing node adjacent to the central mesenteric vascular pedicle measuring 1.0 cm in short axis (series 2, image 258). Mild adjacent haziness of the central mesenteric vascular pedicle. Otherwise unremarkable.     1.  Compared 11/18/2021, increased bilateral upper lobe predominant pulmonary opacities compatible with organizing pneumonia pattern lung injury. Considerations include viral infection and/or medication-induced pulmonary injury. 2.  Background of clustered nodules and nodular consolidation compatible with chronic airway infection. 3.  No definite evidence of thoracic metastatic disease. 4.  Increased pneumobilia and biliary ductal dilation. Correlate with laboratory evidence of biliary 
 obstruction if indicated. Report dictated by: ***** *****, MD, signed by: ***** *****, MD Department of Radiology and Biomedical Imaging      I reviewed CT with the patient  I interpret this as stable disease
T19	SectionSkip 17863 17886	Pathology  04/19/21 EUS
T20	SectionSkip 17888 18617	FINAL PATHOLOGIC DIAGNOSIS    Pancreas, mass, endoscopic ultrasound-guided biopsy: Adenocarcinoma; see comment.     COMMENT:  The biopsy shows infiltrative glands and rare single cells in  desmoplastic stroma.  Marked nuclear pleomorphism and rare foamy  cytoplasm are present, as well as luminal necrosis.  In the context of a  large mass, the findings indicate adenocarcinoma.    Immunostain for DPC4 will be reported by addendum.  UCSF500 molecular testing is in process and will be reported separately.  Drs. *****-*****  *****, ***** *****, and ***** ***** reviewed the H&E slide with  concurrence.  These results were communicated by secure email to Dr. ***** by Dr. ***** on 04/21/2021 at 5:45 p.m.      Genomics  Not done
T21	SectionAnnotate 18622 18641	Assessment and Plan
T22	PROBLEM 299 324	pancreatic adenocarcinoma
T23	ClinicalCondition 519 532	aspergillosis
T24	MedicationName 547 551	vori
T25	TEST 601 608	imaging
T26	PROBLEM 613 626	aspergillosis
T27	PROBLEM 642 659	a pancreatic mass
T28	TEST 664 694	Staging CT scan of the abdomen
T29	PROBLEM 715 732	nodal involvement
T30	PROBLEM 737 806	invasion of the duodenum and abutment of the superior mesenteric vein
T31	PROBLEM 808 827	partial obstruction
T32	PROBLEM 902 926	acute symptomatic anemia
T33	TREATMENT 932 943	transfusion
T34	TREATMENT 948 952	iron
T35	PROBLEM 967 972	bleed
T36	ClinicalCondition 977 1011	pancreatic uncinate adenocarconima
T37	PROBLEM 1017 1042	invasion to duodenal wall
T38	TEST 1047 1050	EGD
T39	TEST 1051 1054	EUS
T40	TEST 1060 1068	biopsies
T41	PROBLEM 1093 1107	adenocarcinoma
T42	TREATMENT 1115 1127	intervention
T43	PROBLEM 1141 1146	fever
T44	PROBLEM 1152 1164	leukocytosis
T45	TREATMENT 1188 1197	procedure
T46	TREATMENT 1228 1231	abx
T47	TEST 1235 1256	further investigation
T48	PROBLEM 1344 1377	sudden onset respiratory distress
T49	PROBLEM 1393 1399	sepsis
T50	PROBLEM 1413 1450	chronic hypoxemic respiratory failure
T51	PROBLEM 1455 1466	R-sided PNA
T52	TREATMENT 1551 1561	FOLFIRINOX
T53	TREATMENT 1609 1625	C Diff treatment
T54	TREATMENT 1627 1632	Vanco
T55	PROBLEM 1652 1672	c diff stool antigen
T56	MedicationRegimen 1696 1706	FOLFIRINOX
T57	PROBLEM 1770 1785	CBD obstruction
T58	PROBLEM 1787 1813	gastric outlet obstruction
T59	PROBLEM 1815 1835	duodenal obstruction
T60	TREATMENT 1840 1866	stents to duodenum and CBD
T61	PROBLEM 1872 1886	poor PO intake
T62	PROBLEM 1908 1920	pancreatitis
T63	TEST 1935 1942	EGD/EUS
T64	TEST 1943 1947	ERCP
T65	TREATMENT 1975 2010	biliary and duodenal 
 metal stents
T66	ClinicalCondition 2044 2064	nonocclusive thrombi
T67	TREATMENT 2155 2168	C1D1 Gem/Cape
T68	TREATMENT 2173 2182	treatment
T69	TEST 2196 2199	HGB
T71	TreatmentType 2278 2289	1 unit PRBC
T72	TEST 2303 2305	CT
T73	PROBLEM 2324 2342	increased RUQ pain
T74	PROBLEM 2401 2437	large pancreatic head/unicinate mass
T75	PROBLEM 2442 2489	new suspicious lesions in the abdomen or pelvis
T76	PROBLEM 2518 2549	pancreatic inflammatory changes
T77	TREATMENT 2576 2612	duodenal and common bile duct stents
T78	PROBLEM 2618 2661	further decrease in biliary ductal dilation
T79	PROBLEM 2681 2707	new rectal wall thickening
T80	PROBLEM 2712 2721	hyperemia
T81	PROBLEM 2740 2758	large stool burden
T82	PROBLEM 2763 2773	distention
T83	PROBLEM 2791 2808	stercoral colitis
T84	PROBLEM 2838 2917	slight interval increase in size of mediastinal and bilateral hilar lymph nodes
T85	PROBLEM 2928 2947	borderline enlarged
T86	TEST 2951 2967	CT size criteria
T87	PROBLEM 3001 3029	patchy groundglass opacities
T88	PROBLEM 3034 3055	centrilobular nodules
T89	TEST 3125 3140	slice thickness
T90	TEST 3149 3156	studies
T91	PROBLEM 3198 3213	acute infection
T92	PROBLEM 3224 3239	viral infection
T93	PROBLEM 3243 3256	drug reaction
T94	TEST 3315 3333	remote prior study
T95	TREATMENT 3369 3380	Gemcitabine
T96	TREATMENT 3383 3395	Capecitabine
T97	TEST 3503 3506	HGB
T98	TREATMENT 3540 3544	PRBC
T99	PROBLEM 3599 3620	CT CAP stable disease
T100	TEST 3747 3753	images
T101	PROBLEM 3794 3816	tumor low in mesentery
T102	TreatmentType 3847 3854	Rad Onc
T103	TREATMENT 3859 3875	bleeding control
T104	PROBLEM 3934 3968	locally advanced pancreas 
 cancer
T105	PROBLEM 3986 3998	unresectable
T106	PROBLEM 4006 4036	extensive vascular involvement
T107	TreatmentType 4102 4129	continuing systemic regimen
T108	TreatmentType 4133 4159	starting different regimen
T109	TreatmentType 4170 4179	radiation
T110	TreatmentType 4307 4319	radiotherapy
T111	TREATMENT 4341 4370	5 fraction low dose radiation
T112	PROBLEM 4386 4407	his duodenal bleeding
T113	TREATMENT 4409 4424	5 fraction SBRT
T114	TREATMENT 4429 4442	tumor control
T115	TREATMENT 4447 4471	25 fraction capecitabine
T116	TREATMENT 4472 4484	radiotherapy
T117	TREATMENT 4489 4502	tumor control
T118	TREATMENT 4508 4512	SBRT
T119	TREATMENT 4514 4523	treatment
T120	TREATMENT 4655 4667	radiotherapy
T121	TREATMENT 4697 4706	radiation
T122	TEST 4718 4731	CT simulation
T123	TREATMENT 4733 4751	radiation planning
T124	TREATMENT 4757 4774	actual treatments
T125	TREATMENT 4800 4820	fractionated therapy
T126	TREATMENT 4837 4858	higher radiation dose
T127	PROBLEM 4862 4871	the tumor
T128	TREATMENT 4909 4922	local control
T129	TEST 4936 4951	randomized data
T130	PROBLEM 4978 4982	SBRT
T131	TREATMENT 5152 5156	SBRT
T132	TREATMENT 5161 5181	Fractionated chemoRT
T133	TREATMENT 5185 5216	new multiagent systemic therapy
T134	PROBLEM 5353 5361	vomiting
T135	PROBLEM 5383 5394	hematemesis
T136	TREATMENT 5418 5435	the jejunal stent
T137	TREATMENT 5477 5480	XRT
T138	TEST 5543 5557	repeat CT scan
T139	TreatmentType 5585 5588	Abx
T140	Symptom 5686 5692	Fevers
T141	TREATMENT 5770 5773	abx
T142	PROBLEM 5887 5893	Cancer
T143	PROBLEM 5909 5926	prostate 
 cancer
T144	ClinicalCondition 5931 5945	Cardiac arrest
T145	PROBLEM 5966 5978	Constipation
T146	PROBLEM 5983 6036	Mild    COPD (chronic obstructive pulmonary disease)
T147	PROBLEM 6053 6070	Diabetes mellitus
T148	PROBLEM 6098 6145	Mild    GERD (gastroesophageal reflux disease)
T149	PROBLEM 6155 6167	Hearing loss
T150	PROBLEM 6173 6185	Hypertension
T151	PROBLEM 6191 6203	Osteoporosis
T152	PROBLEM 6212 6240	Moderate    Prostate cancer
T153	PROBLEM 6257 6266	Psoriasis
T154	ProcedureName 6329 6340	EYE SURGERY
T155	TREATMENT 6347 6364	IR PORT PLACEMENT
T156	TREATMENT 6529 6552	prostate cancer surgery
T157	TREATMENT 6559 6575	PROSTATE SURGERY
T158	PROBLEM 6616 6631	Known Allergies
T159	TREATMENT 6636 6666	Current Outpatient Medications
T160	TREATMENT 6697 6720	acetaminophen (TYLENOL)
T161	TREATMENT 6748 6768	bisacodyL (DULCOLAX)
T162	TREATMENT 6794 6845	budesonide-glycopyr-formoterol (BREZTRI AEROSPHERE)
T163	TREATMENT 6913 6950	calcium carbonate-vitamin D (OSCAL D)
T164	TREATMENT 7031 7051	CALCIUM CITRATE ORAL
T165	TREATMENT 7074 7109	Scheduled    capecitabine (XELODA)
T166	TREATMENT 7274 7279	CREON
T167	TREATMENT 7368 7386	denosumab (PROLIA)
T168	TREATMENT 7512 7532	dronabinoL (MARINOL)
T169	TREATMENT 7646 7670	famotidine (PEPCID ORAL)
T170	TREATMENT 7671 7696	Oral    GLIMEPIRIDE ORAL
T171	TREATMENT 7726 7771	Scheduled    lipase-protease-amylase (CREON)
T172	TREATMENT 7860 7869	melatonin
T173	TREATMENT 7907 7942	Scheduled    mirtazapine (REMERON)
T174	TREATMENT 8003 8022	multivitamin tablet
T175	TREATMENT 8064 8096	Centrum    ondansetron (ZOFRAN)
T176	TREATMENT 8131 8154	pantoprazole (PROTONIX)
T177	TREATMENT 8176 8188	Pantoprazole
T178	TREATMENT 8220 8232	Pantoprazole
T179	TREATMENT 8326 8349	pantoprazole (PROTONIX)
T180	TREATMENT 8381 8410	polyethylene glycol (MIRALAX)
T181	TREATMENT 8429 8471	Scheduled    prochlorperazine (COMPAZINE)
T182	TREATMENT 8507 8522	senna (SENOKOT)
T183	TREATMENT 8555 8590	Scheduled    sucralfate (CARAFATE)
T184	ClinicalCondition 8729 8741	Hearing loss
T185	ClinicalCondition 8755 8768	Heart disease
T186	ClinicalCondition 8782 8801	High blood pressure
T187	PROBLEM 8815 8827	Hearing loss
T188	PROBLEM 8841 8853	Hearing loss
T189	PROBLEM 8867 8879	Hearing loss
T190	PROBLEM 8894 8912	Pulmonary fibrosis
T191	PROBLEM 8939 8967	hereditary pattern of cancer
T192	TEST 9540 9550	Pain Score
T193	TEST 9648 9650	lb
T194	TEST 9676 9678	lb
T195	TEST 9683 9685	oz
T196	TEST 9692 9708	ECOG performance
T197	TEST 9709 9715	status
T198	PROBLEM 9720 9731	Symptomatic
T199	PROBLEM 9759 9762	NAD
T200	PROBLEM 9832 9852	respiratory distress
T201	PROBLEM 9857 9862	cough
T202	PROBLEM 9901 9906	edema
T203	TEST 9965 9978	Prior Testing
T204	TEST 10165 10170	Value
T205	TEST 10179 10182	WBC
T206	TEST 10183 10188	Count
T207	TEST 10207 10210	Abs
T208	TEST 10211 10222	Neutrophils
T209	TEST 10242 10252	Hemoglobin
T210	TEST 10258 10259	L
T211	TEST 10275 10285	Hematocrit
T212	TEST 10309 10323	Platelet Count
T213	TEST 10342 10352	Creatinine
T214	TEST 10372 10381	Bilirubin
T215	TEST 10383 10388	Total
T216	TEST 10407 10427	Alkaline Phosphatase
T217	TEST 10445 10448	AST
T218	TEST 10466 10486	Alanine transaminase
T219	TEST 10504 10511	Albumin
T220	TEST 10513 10518	Serum
T221	TEST 10521 10527	Plasma
T222	TEST 10550 10553	INR
T223	TEST 10572 10578	Sodium
T224	TEST 10580 10585	Serum
T225	TEST 10588 10594	Plasma
T226	TEST 10613 10622	Potassium
T227	TEST 10624 10629	Serum
T228	TEST 10632 10638	Plasma
T229	TEST 10657 10664	Calcium
T230	TEST 10673 10678	Serum
T231	TEST 10681 10687	Plasma
T232	TEST 10707 10718	Lab Results
T233	TEST 10745 10751	Cancer
T234	TEST 10752 10759	Antigen
T235	TEST 10782 10796	Cancer Antigen
T236	TEST 10819 10833	Cancer Antigen
T237	TEST 10939 10954	imaging studies
T238	TEST 11057 11137	CT Abdomen /Pelvis with and without Contrast    CT Abdomen /Pelvis with Contrast
T239	TEST 11166 11168	CT
T240	TEST 11169 11197	ABDOMEN/PELVIS WITH CONTRAST
T241	PROBLEM 11250 11275	Pancreatic adenocarcinoma
T242	TEST 11276 11291	Restaging scans
T243	TEST 11306 11323	CT abdomen pelvis
T244	TEST 11346 11374	CT of the abdomen and pelvis
T245	TREATMENT 11403 11410	Iohexol
T246	TEST 11476 11490	chest findings
T247	TEST 11539 11558	the CT of the chest
T248	PROBLEM 11585 11647	Persistent mild intrahepatic and extrahepatic biliary dilation
T249	PROBLEM 11653 11674	decreased pneumobilia
T250	TREATMENT 11696 11718	common bile duct stent
T251	TREATMENT 11733 11754	Prior cholecystectomy
T252	PROBLEM 11756 11794	Similar fluid in the gallbladder fossa
T253	PROBLEM 11847 11898	ill-defined pancreatic mass in the uncinate process
T254	TEST 11948 11953	image
T255	PROBLEM 12096 12138	Benign cyst in the right kidney lower pole
T256	PROBLEM 12151 12209	Persistent encasement of the third portion of the duodenum
T257	PROBLEM 12213 12232	the pancreatic mass
T258	PROBLEM 12234 12280	Similar enhancing soft tissue within the stent
T259	PROBLEM 12297 12302	tumor
T260	TREATMENT 12347 12361	duodenal stent
T261	TREATMENT 12363 12389	Interval gastrojejunostomy
T262	TREATMENT 12395 12406	axios stent
T263	PROBLEM 12417 12437	Nondistended stomach
T264	PROBLEM 12439 12453	Diverticulosis
T265	PROBLEM 12474 12494	acute diverticulitis
T266	PROBLEM 12510 12582	Moderate atherosclerotic disease of the abdominal aorta and its branches
T267	PROBLEM 12584 12638	Unchanged obliteration of the superior mesenteric vein
T268	PROBLEM 12655 12674	the pancreatic mass
T269	PROBLEM 12676 12684	The mass
T270	PROBLEM 12697 12754	similar abutment of the distal superior mesenteric artery
T271	PROBLEM 12756 12771	Lymphadenopathy
T272	PROBLEM 12773 12803	Similar mesenteric lymph nodes
T273	PROBLEM 12816 12824	the mass
T274	PROBLEM 12892 12899	ascites
T275	PROBLEM 12909 12953	Contrast layering dependently in the bladder
T276	PROBLEM 13000 13018	suspicious lesions
T277	PROBLEM 13049 13099	Similar medium fat-containing left inguinal hernia
T278	TREATMENT 13101 13113	Lines/drains
T279	TEST 13211 13222	CTDIvol Max
T280	TEST 13233 13236	DLP
T281	PROBLEM 13352 13367	pancreatic mass
T282	PROBLEM 13428 13462	Similar peripancreatic lymph nodes
T283	TREATMENT 13468 13509	Interval placement of gastrojejunal stent
T284	PROBLEM 13526 13546	proximal obstruction
T285	TEST 13552 13560	CT Chest
T286	TEST 13603 13605	CT
T287	TEST 13673 13681	CT chest
T288	TEST 13711 13758	Serial 1.25 mm axial images 
 through the chest
T289	TREATMENT 13801 13821	intravenous contrast
T290	TREATMENT 13823 13830	Iohexol
T291	TEST 13928 13939	CTDIvol Max
T292	TEST 13950 13953	DLP
T293	TREATMENT 13978 13999	Right chest wall port
T294	TREATMENT 14005 14008	tip
T295	PROBLEM 14096 14156	waxing and waning multifocal peribronchovascular groundglass
T296	PROBLEM 14229 14254	Bronchial wall thickening
T297	PROBLEM 14309 14325	pleural effusion
T298	PROBLEM 14329 14341	pneumothorax
T299	PROBLEM 14356 14389	Unchanged mediastinal lymph nodes
T300	PROBLEM 14460 14480	pericardial effusion
T301	PROBLEM 14482 14535	Severe coronary artery atherosclerotic calcifications
T302	PROBLEM 14617 14643	suspicious osseous lesions
T303	TEST 14673 14704	dedicated Abdomen and Pelvis CT
T304	PROBLEM 14743 14803	waxing and waning multifocal peribronchovascular groundglass
T305	PROBLEM 14821 14844	an organizing pneumonia
T306	PROBLEM 14856 14867	lung injury
T307	PROBLEM 14895 14904	infection
T308	PROBLEM 14908 14921	drug reaction
T309	PROBLEM 14926 14966	new or enlarging solid pulmonary nodules
T310	PROBLEM 14971 15026	Persistent bronchial wall thickening of the lower lobes
T311	PROBLEM 15050 15076	airway spread of infection
T312	TEST 15182 15212	Biomedical Imaging    CT Chest
T313	TEST 15255 15257	CT
T314	PROBLEM 15297 15322	Pancreatic adenocarcinoma
T315	PROBLEM 15326 15335	latent tB
T316	PROBLEM 15337 15343	fevers
T317	TEST 15356 15367	Thoracic CT
T318	TEST 15418 15463	Serial 1.25 mm axial images through the chest
T319	TREATMENT 15506 15526	intravenous contrast
T320	TREATMENT 15528 15535	Iohexol
T321	TEST 15631 15634	DLP
T322	TREATMENT 15678 15705	Right chest port 
 catheter
T323	PROBLEM 15761 15847	Increased upper lobe predominant peribronchovascular groundglass/perilobular opacities
T324	PROBLEM 15849 15907	Increased atelectasis in the right middle lobe and lingula
T325	PROBLEM 15909 15957	New nodular consolidation in the left lower lobe
T326	PROBLEM 15994 16010	pleural effusion
T327	PROBLEM 16025 16048	A few mediastinal nodes
T328	TEST 16088 16105	an AP window node
T329	TEST 16166 16171	image
T330	PROBLEM 16208 16229	regional inflammation
T331	PROBLEM 16231 16270	Mild diffuse esophageal wall thickening
T332	PROBLEM 16328 16348	pericardial effusion
T333	PROBLEM 16350 16385	Mild coronary artery calcifications
T334	PROBLEM 16410 16427	suspicious lesion
T335	PROBLEM 16446 16467	Increased pneumobilia
T336	PROBLEM 16473 16527	intrahepatic and extra hepatic biliary ductal dilation
T337	PROBLEM 16529 16607	Thickened, enhancing walls of the hepatic, cystic, and upper common bile ducts
T338	TEST 16620 16630	prior exam
T339	TREATMENT 16632 16671	Partially imaged common bile duct stent
T340	TREATMENT 16746 16780	Partially imaged gastrostomy stent
T341	TREATMENT 16800 16832	a left upper quadrant bowel loop
T342	TREATMENT 16834 16856	Partially imaged stent
T343	PROBLEM 16923 16953	Mildly enlarged enhancing node
T344	PROBLEM 17060 17125	Mild adjacent haziness of the central mesenteric vascular pedicle
T345	PROBLEM 17180 17242	increased bilateral upper lobe predominant pulmonary opacities
T346	PROBLEM 17259 17299	organizing pneumonia pattern lung injury
T347	PROBLEM 17324 17339	viral infection
T348	PROBLEM 17347 17382	medication-induced pulmonary injury
T349	PROBLEM 17402 17419	clustered nodules
T350	PROBLEM 17424 17445	nodular consolidation
T351	PROBLEM 17462 17486	chronic airway infection
T352	PROBLEM 17516 17543	thoracic metastatic disease
T353	PROBLEM 17549 17570	Increased pneumobilia
T354	PROBLEM 17575 17598	biliary ductal dilation
T355	PROBLEM 17638 17659	biliary 
 obstruction
T356	TEST 17801 17803	CT
T357	TEST 17883 17886	EUS
T358	PROBLEM 17928 17932	mass
T359	TEST 17934 17955	endoscopic ultrasound
T360	TEST 17956 17969	guided biopsy
T361	PROBLEM 17971 17985	Adenocarcinoma
T362	TEST 18014 18024	The biopsy
T363	PROBLEM 18031 18050	infiltrative glands
T364	PROBLEM 18055 18096	rare single cells in  desmoplastic stroma
T365	PROBLEM 18099 18126	Marked nuclear pleomorphism
T366	PROBLEM 18131 18152	rare foamy  cytoplasm
T367	PROBLEM 18177 18193	luminal necrosis
T368	PROBLEM 18214 18227	a  large mass
T369	PROBLEM 18251 18265	adenocarcinoma
T370	TEST 18270 18281	Immunostain
T371	TEST 18286 18290	DPC4
T372	TEST 18330 18347	molecular testing
T373	PROBLEM 18695 18730	diagnosed pancreatic adenocarcinoma
T374	PROBLEM 18766 18769	SBO
T375	TREATMENT 18774 18782	stenting
T376	PROBLEM 18787 18812	Pancreatic Adenocarcinoma
T377	TREATMENT 18832 18840	Gem Cape
T378	TREATMENT 18861 18864	XRT
T379	TREATMENT 18894 18910	systemic therapy
T380	TREATMENT 18924 18933	radiation
T381	TEST 18991 18993	CA
T382	PROBLEM 19005 19008	GIB
T383	PROBLEM 19017 19031	tumor invasion
T384	TEST 19086 19089	CBC
T385	TREATMENT 19104 19109	PRBCs
T386	TEST 19118 19121	HGB
T387	PROBLEM 19136 19160	biliary duct obstruction
T388	TREATMENT 19168 19197	biliary metal stent placement
T389	PROBLEM 19250 19273	small bowel obstruction
T390	PROBLEM 19281 19298	tumor obstruction
T391	TREATMENT 19306 19309	EGD
T392	TREATMENT 19314 19341	placement of duodenal stent
T393	PROBLEM 19402 19408	C Diff
T394	PROBLEM 19444 19452	abd pain
T395	TREATMENT 19464 19469	Creon
T396	PROBLEM 19473 19486	Aspergillosis
T397	PROBLEM 19548 19581	Chronic lung infectious 
 process
T398	ProcedureName 19654 19660	bronch
T399	TEST 19689 19697	cultures
T400	TEST 19803 19805	wt
T401	TreatmentType 19857 19895	aggressive nutritional supplementation
T402	PROBLEM 19900 19904	Pain
T403	TEST 19906 19921	Pain assessment
T404	PROBLEM 20039 20047	Insomnia
T405	MedicationName 20091 20098	Remeron
T406	MedicationName 20103 20112	melatonin
T407	TREATMENT 20133 20155	nutrition consultation
T408	TreatmentType 20167 20182	Pain management
T409	PROBLEM 20235 20248	pain symptoms
T410	TREATMENT 20443 20462	this patient's care
T411	TREATMENT 20521 20542	any billed procedures
T412	TEST 20680 20685	tests
T413	TEST 20884 20899	this evaluation
T414	TEST 21075 21090	this evaluation
T415	TEST 21097 21113	telehealth tools
T416	PROBLEM 21321 21344	patient's active cancer
T417	PROBLEM 21356 21382	a life-threatening illness
T418	TREATMENT 21419 21436	the defined types
T419	Age 245 247	78
T420	ClinicalCondition 299 324	pancreatic adenocarcinoma
T421	Site 336 361	pancreatic head/unicinate
R1	SiteOf Arg1:T421 Arg2:T420	
A1	ChronicVal T23 non-chronic
A2	ContinuityVal T23 unclear
A3	TreatmentContinuityVal T24 finished
A4	TreatmentTypeVal T24 others
A5	TreatmentIntentVal T24 others
A6	TreatmentCategory T24 Others
R2	TreatmentAdministeredForProblem Treatment:T24 Prob:T23	
T422	ClinicalCondition 613 626	aspergillosis
A7	ChronicVal T422 non-chronic
A8	ContinuityVal T422 stable
T423	Radiology 601 608	imaging
A9	IntentVal T423 others
R3	TestOrProcedureConductedForProblem Test:T423 Prob:T422	
T424	RadPathResult 644 659	pancreatic mass
A10	RadPathResultVal T424 InitialCancerDiagnosis
R4	ResultOfTest Desc:T424 Test:T423	
T425	Radiology 672 694	CT scan of the abdomen
A11	IntentVal T425 staging
T426	LymphNodeInvolvement 715 732	nodal involvement
A12	EpisodeDescription T426 FirstOccurrence
R5	TestOrProcedureReveals Test:T425 Desc:T426	
T427	LocalInvasion 737 745	invasion
A13	EpisodeDescription T427 FirstOccurrence
T428	Site 753 761	duodenum
R6	SiteOf Arg1:T428 Arg2:T427	
R7	TestOrProcedureReveals Test:T425 Desc:T427	
T429	Site 782 806	superior mesenteric vein
T430	LocalInvasion 766 774	abutment
A14	EpisodeDescription T430 FirstOccurrence
R8	SiteOf Arg1:T429 Arg2:T430	
R9	TestOrProcedureReveals Test:T425 Desc:T430	
T431	RadPathResult 808 827	partial obstruction
A15	RadPathResultVal T431 Others
R10	ResultOfTest Desc:T431 Test:T425	
T432	ClinicalCondition 902 926	acute symptomatic anemia
A16	ChronicVal T432 non-chronic
A17	ContinuityVal T432 improving
T433	MedicationName 932 943	transfusion
A18	TreatmentTypeVal T433 others
A19	TreatmentIntentVal T433 others
A20	TreatmentCategory T433 Others
T434	MedicationName 948 952	iron
A21	TreatmentTypeVal T434 others
A22	TreatmentIntentVal T434 others
A23	TreatmentCategory T434 Others
R11	TreatmentAdministeredForProblem Treatment:T433 Prob:T432	
R12	TreatmentAdministeredForProblem Treatment:T434 Prob:T432	
T435	Symptom 967 972	bleed
A24	TreatmentTypeVal T435 others
A25	TreatmentIntentVal T435 others
A26	TreatmentCategory T435 Others
A27	IsPresentOnFirstCancerDiagnosis T435 no
A28	IsCausedByDiagnosedCancer T435 yes
A29	ContinuityVal T435 stopped
A30	ChronicVal T36 chronic
A31	ContinuityVal T36 stable
T436	LocalInvasion 1017 1025	invasion
A32	EpisodeDescription T436 FirstOccurrence
T437	Site 1029 1042	duodenal wall
R13	SiteOf Arg1:T437 Arg2:T436	
T438	ProcedureName 1047 1050	EGD
A33	IntentVal T438 diagnosis
T439	Radiology 1051 1054	EUS
A34	IntentVal T439 diagnosis
T440	ProcedureName 1060 1068	biopsies
A35	IntentVal T440 diagnosis
T441	RadPathResult 1093 1107	adenocarcinoma
A36	RadPathResultVal T441 InitialCancerDiagnosis
R14	ResultOfTest Desc:T441 Test:T440	
R15	ResultOfTest Desc:T441 Test:T439	
T442	Symptom 1141 1146	fever
A37	IsPresentOnFirstCancerDiagnosis T442 no
A38	IsCausedByDiagnosedCancer T442 no
A39	ChronicVal T442 non-chronic
A40	ContinuityVal T442 stopped
T443	Symptom 1152 1164	leukocytosis
A41	IsPresentOnFirstCancerDiagnosis T443 no
A42	IsCausedByDiagnosedCancer T443 no
A43	ChronicVal T443 non-chronic
A44	ContinuityVal T443 stopped
T444	ProcedureName 1188 1197	procedure
A45	IntentVal T444 diagnosis
R16	ConditionOrTreatmentCausesProblem Treatment:T444 Prob:T443	
R17	ConditionOrTreatmentCausesProblem Treatment:T444 Prob:T442	
T445	TreatmentType 1228 1231	abx
A46	NegationModalityVal T445 negated
A47	TreatmentTypeVal T445 others
A48	TreatmentIntentVal T445 others
T446	Symptom 1357 1377	respiratory distress
A49	IsPresentOnFirstCancerDiagnosis T446 no
A50	IsCausedByDiagnosedCancer T446 no
A51	ChronicVal T446 non-chronic
A52	ContinuityVal T446 stopped
T447	ClinicalCondition 1393 1399	sepsis
A53	ChronicVal T447 non-chronic
A54	ContinuityVal T447 stopped
R18	ConditionOrTreatmentCausesProblem Treatment:T447 Prob:T446	
T448	ClinicalCondition 1404 1450	acute on chronic hypoxemic respiratory failure
A55	ChronicVal T448 non-chronic
A56	ContinuityVal T448 worsening
T449	ClinicalCondition 1463 1466	PNA
A57	ChronicVal T449 non-chronic
A58	ContinuityVal T449 stopped
T450	Laterality 1455 1462	R-sided
R19	ConditionOrTreatmentCausesProblem Treatment:T449 Prob:T446	
R20	ConditionOrTreatmentCausesProblem Treatment:T449 Prob:T448	
T451	Datetime 1472 1480	04/29/21
T452	MedicationRegimen 1551 1561	FOLFIRINOX
A59	NegationModalityVal T452 planned_in_future
A60	TreatmentContinuityVal T452 planned
A61	TreatmentTypeVal T452 maintenance
A62	TreatmentIntentVal T452 palliative
T453	ClinicalCondition 1609 1615	C Diff
A63	ChronicVal T453 non-chronic
A64	ContinuityVal T453 stopped
T454	MedicationName 1627 1632	Vanco
A65	TreatmentContinuityVal T454 finished
A66	TreatmentTypeVal T454 others
A67	TreatmentIntentVal T454 others
A68	TreatmentCategory T454 Others
R21	TreatmentAdministeredForProblem Treatment:T454 Prob:T453	
T455	LabTestResult 1652 1672	c diff stool antigen
A69	LabTestResultVal T455 normal
A70	NegationModalityVal T455 hypothetical_in_future
A71	NegationModalityVal T56 planned_in_future
A72	TreatmentTypeVal T56 maintenance
A73	TreatmentIntentVal T56 palliative
T456	ClinicalCondition 1770 1785	CBD obstruction
A74	ChronicVal T456 non-chronic
A75	ContinuityVal T456 new
T457	ClinicalCondition 1787 1813	gastric outlet obstruction
A76	ChronicVal T457 non-chronic
A77	ContinuityVal T457 new
T458	ClinicalCondition 1815 1835	duodenal obstruction
A78	ChronicVal T458 non-chronic
A79	ContinuityVal T458 new
T459	ProcedureName 1840 1846	stents
A80	IntentVal T459 others
A81	TreatmentTypeVal T459 others
A82	TreatmentCategory T459 Supportive
R22	TestOrProcedureConductedForProblem Test:T459 Prob:T458	
R23	TestOrProcedureConductedForProblem Test:T459 Prob:T457	
R24	TestOrProcedureConductedForProblem Test:T459 Prob:T456	
T460	Site 1850 1858	duodenum
T461	Site 1863 1866	CBD
T462	Symptom 1872 1886	poor PO intake
A83	IsPresentOnFirstCancerDiagnosis T462 yes
A84	IsCausedByDiagnosedCancer T462 yes
A85	ContinuityVal T462 stopped
T463	ClinicalCondition 1908 1920	pancreatitis
A86	ChronicVal T463 non-chronic
A87	ContinuityVal T463 stopped
T464	ProcedureName 1935 1938	EGD
A88	IntentVal T464 others
T465	Radiology 1939 1942	EUS
A89	IntentVal T465 others
T466	ProcedureName 1943 1947	ERCP
A90	IntentVal T466 others
T467	Datetime 1948 1956	05/06/21
R25	HappensAtOnDuring Arg1:T467 Arg2:T466	
R26	HappensAtOnDuring Arg1:T467 Arg2:T465	
R27	HappensAtOnDuring Arg1:T467 Arg2:T464	
T468	ProcedureName 1962 1971	placement
A91	IntentVal T468 others
R28	HappensAtOnDuring Arg1:T468 Arg2:T467	
A92	ChronicVal T66 non-chronic
A93	ContinuityVal T66 stopped
T469	Site 2076 2100	superior mesenteric vein
R29	SiteOf Arg1:T469 Arg2:T66	
T470	Datetime 2123 2131	06/03/21
T471	Cycles 2155 2159	C1D1
T472	MedicationRegimen 2160 2168	Gem/Cape
A94	NegationModalityVal T472 negated
A95	TreatmentContinuityVal T472 started
A96	TreatmentTypeVal T472 maintenance
A97	TreatmentIntentVal T472 palliative
T473	LabTestResult 2196 2203	HGB 7.5
A98	LabTestResultVal T473 abnormal
A99	NegationModalityVal T71 negated
T70	Datetime 2251 2259	06/06/21
R31	HappensAtOnDuring Arg1:T70 Arg2:T71	
T474	Datetime 2293 2301	06/08/21
T475	Radiology 2303 2309	CT CAP
A100	IntentVal T475 others
R32	HappensAtOnDuring Arg1:T474 Arg2:T475	
T476	Symptom 2338 2342	pain
A101	IsPresentOnFirstCancerDiagnosis T476 no
A102	IsCausedByDiagnosedCancer T476 yes
A103	ContinuityVal T476 stopped
T477	Site 2334 2337	RUQ
R33	SiteOf Arg1:T477 Arg2:T476	
R34	TestOrProcedureConductedForProblem Test:T475 Prob:T476	
T478	SectionSkip 2344 3349	IMPRESSION:  - Compared to 05/12/2021, unchanged size of large pancreatic head/unicinate mass. No new suspicious lesions in the abdomen or pelvis.   - Interval resolution of pancreatic inflammatory changes.  - Unchanged position of duodenal and common bile duct stents with further decrease in biliary ductal dilation.   - Suggestion of new rectal wall thickening and hyperemia in the setting of large stool burden and distention that may reflect stercoral colitis.   - Compared to 03/15/2021, slight interval increase in size of mediastinal and bilateral hilar lymph nodes which are borderline enlarged by CT size criteria. Additional apparent increase in patchy groundglass opacities and centrilobular nodules although direct comparison is somewhat limited due to differences in slice thickness between studies. These findings are favored to represent acute infection including viral infection or drug reaction and are similar to although less conspicuous than on more remote prior study from 11/10/2020
A104	SectionSkipType T478 radiology_report
T479	Datetime 3354 3362	06/09/21
T480	Cycles 3364 3368	C1D1
T481	MedicationRegimen 3369 3395	Gemcitabine + Capecitabine
A105	TreatmentContinuityVal T481 started
A106	TreatmentTypeVal T481 maintenance
A107	TreatmentIntentVal T481 palliative
R30	BeginsOnOrAt Arg1:T470 Arg2:T472	
R35	TreatmentDesc Therapy:T471 Desc:T472	
R36	TreatmentDesc Therapy:T480 Desc:T481	
R37	HappensAtOnDuring Arg1:T479 Arg2:T481	
T482	Datetime 3398 3406	06/15/21
T483	Datetime 3471 3479	06/23/21
T484	Cycles 3481 3486	C1D15
T485	MedicationRegimen 3487 3495	Gem/Cape
A108	TreatmentContinuityVal T485 continuing
A109	TreatmentTypeVal T485 maintenance
A110	TreatmentIntentVal T485 palliative
R38	TreatmentDesc Therapy:T484 Desc:T485	
R39	HappensAtOnDuring Arg1:T483 Arg2:T485	
T486	LabTestResult 3503 3510	HGB 7.9
A111	LabTestResultVal T486 abnormal
T487	Datetime 3512 3520	06/25/21
T488	TreatmentType 3540 3544	PRBC
A112	TreatmentContinuityVal T488 finished
A113	TreatmentTypeVal T488 others
A114	TreatmentIntentVal T488 others
T489	TreatmentDosage 3533 3539	1 unit
R40	TreatmentDesc Therapy:T489 Desc:T488	
T490	Datetime 3546 3554	07/07/21
T491	Datetime 3572 3580	07/21/21
T492	Datetime 3589 3597	08/01/21
T493	Datetime 3623 3631	08/04/21
T494	Datetime 3639 3647	08/10/21
T495	Cycles 3556 3560	C2D1
T496	Cycles 3582 3587	C2D15
T497	Cycles 3633 3637	C3D1
T498	MedicationRegimen 3561 3569	Gem/Cape
A115	TreatmentContinuityVal T498 continuing
A116	TreatmentTypeVal T498 maintenance
A117	TreatmentIntentVal T498 palliative
R41	TreatmentDesc Therapy:T495 Desc:T498	
R42	TreatmentDesc Therapy:T498 Desc:T496	
R43	TreatmentDesc Therapy:T498 Desc:T497	
R44	HappensAtOnDuring Arg1:T490 Arg2:T495	
R45	HappensAtOnDuring Arg1:T491 Arg2:T496	
R46	HappensAtOnDuring Arg1:T493 Arg2:T497	
T499	Radiology 3599 3605	CT CAP
A118	IntentVal T499 TreatmentAssessment
T500	RadPathResult 3606 3620	stable disease
A119	RadPathResultVal T500 DiseaseStability
R47	ResultOfTest Desc:T500 Test:T499	
R48	HappensAtOnDuring Arg1:T492 Arg2:T499	
T501	Datetime 3881 3889	08/11/21
T502	LocalInvasion 3755 3769	Not resectable
A120	EpisodeDescription T502 Others
T503	Site 3777 3780	SMA
R49	SiteOf Arg1:T503 Arg2:T502	
T504	Site 3807 3816	mesentery
T505	LocalInvasion 3934 3950	locally advanced
T506	ClinicalCondition 3951 3959;3962 3968	pancreas cancer
T507	LocalInvasion 4006 4036	extensive vascular involvement
T508	Site 4044 4065	root of the mesentery
R50	SiteOf Arg1:T508 Arg2:T507	
T509	Datetime 4184 4192	08/18/21
T510	Cycles 4194 4199	C3D15
T511	MedicationRegimen 4200 4208	Gem/Cape
A121	TreatmentContinuityVal T511 continuing
A122	TreatmentTypeVal T511 maintenance
A123	TreatmentIntentVal T511 palliative
R51	TreatmentDesc Therapy:T510 Desc:T511	
T512	Datetime 4210 4218	08/25/21
T513	ClinicalCondition 5909 5917;5920 5926	prostate cancer
A124	ChronicVal T513 chronic
A125	ContinuityVal T513 stable
T514	ClinicalCondition 5966 5978	Constipation
A126	ChronicVal T514 chronic
A127	ContinuityVal T514 stable
T515	ClinicalCondition 5992 6036	COPD (chronic obstructive pulmonary disease)
A128	ChronicVal T515 chronic
A129	ContinuityVal T515 stable
T516	ClinicalCondition 6053 6070	Diabetes mellitus
A130	ChronicVal T516 chronic
A131	ContinuityVal T516 stable
T517	ClinicalCondition 6107 6145	GERD (gastroesophageal reflux disease)
A132	ChronicVal T517 chronic
A133	ContinuityVal T517 stable
T518	ClinicalCondition 6173 6185	Hypertension
A134	ChronicVal T518 chronic
A135	ContinuityVal T518 stable
T519	ClinicalCondition 6191 6203	Osteoporosis
A136	ChronicVal T519 chronic
A137	ContinuityVal T519 stable
T520	ClinicalCondition 6225 6240	Prostate cancer
A140	TreatmentTypeVal T102 local
A141	TreatmentIntentVal T102 others
T521	Symptom 3859 3867	bleeding
A142	IsPresentOnFirstCancerDiagnosis T521 no
A143	IsCausedByDiagnosedCancer T521 yes
A144	ChronicVal T521 non-chronic
A145	ContinuityVal T521 unclear
R52	TreatmentAdministeredForProblem Treatment:T102 Prob:T521	
A146	NegationModalityVal T110 hypothetical_in_future
A147	TreatmentTypeVal T110 local
A148	TreatmentIntentVal T110 palliative
T522	Cycles 4341 4342	5
R53	TreatmentDesc Therapy:T522 Desc:T110	
T523	Symptom 4390 4407	duodenal bleeding
A149	IsCausedByDiagnosedCancer T523 yes
A150	ChronicVal T523 non-chronic
A151	ContinuityVal T523 unclear
R54	TreatmentAdministeredForProblem Treatment:T110 Prob:T523	
T524	Cycles 4409 4410	5
R55	TreatmentDesc Therapy:T110 Desc:T524	
T525	RadiationTherapyName 4420 4424	SBRT
A152	NegationModalityVal T525 hypothetical_in_future
A153	TreatmentTypeVal T525 local
A154	TreatmentIntentVal T525 palliative
R56	TreatmentDesc Therapy:T524 Desc:T525	
T526	Cycles 4447 4449	25
T527	RadiationTherapyName 4459 4484	capecitabine-radiotherapy
A155	NegationModalityVal T527 hypothetical_in_future
A156	TreatmentTypeVal T527 local
A157	TreatmentIntentVal T527 palliative
R57	TreatmentDesc Therapy:T526 Desc:T527	
T528	RadiationTherapyName 4508 4512	SBRT
A158	NegationModalityVal T528 hypothetical_in_future
A159	TreatmentTypeVal T528 local
A160	TreatmentIntentVal T528 palliative
T529	Cycles 4541 4542	5
R58	TreatmentDesc Therapy:T529 Desc:T528	
T530	Duration 4581 4588	2 weeks
R59	HappensOverlapping Arg1:T528 Arg2:T530	
T531	ProcedureName 4718 4731	CT simulation
A161	IntentVal T531 others
A162	TreatmentTypeVal T531 others
A163	TreatmentCategory T531 Others
A164	NegationModalityVal T531 hypothetical_in_future
T532	ProcedureName 4733 4751	radiation planning
A165	NegationModalityVal T532 hypothetical_in_future
A166	IntentVal T532 others
A167	TreatmentTypeVal T532 others
A168	TreatmentCategory T532 Others
T533	ProcedureName 4757 4774	actual treatments
A169	NegationModalityVal T533 hypothetical_in_future
A170	IntentVal T533 treatment-palliative
A171	TreatmentTypeVal T533 others
A172	TreatmentCategory T533 Others
T534	TreatmentType 4800 4820	fractionated therapy
A173	NegationModalityVal T534 hypothetical_in_future
A174	TreatmentTypeVal T534 local
A175	TreatmentIntentVal T534 palliative
T535	TreatmentType 5152 5156	SBRT
A176	NegationModalityVal T535 hypothetical_in_future
A177	TreatmentTypeVal T535 local
A178	TreatmentIntentVal T535 palliative
T536	TreatmentType 5161 5181	Fractionated chemoRT
A179	NegationModalityVal T536 hypothetical_in_future
A180	TreatmentTypeVal T536 local
A181	TreatmentIntentVal T536 palliative
T537	TreatmentType 5185 5216	new multiagent systemic therapy
A182	NegationModalityVal T537 hypothetical_in_future
A183	TreatmentTypeVal T537 maintenance
A184	TreatmentIntentVal T537 palliative
T538	TreatmentType 4978 4982	SBRT
A185	NegationModalityVal T538 hypothetical_in_future
A186	TreatmentTypeVal T538 local
A187	TreatmentIntentVal T538 palliative
T539	Datetime 5308 5316	09/01/21
T540	Datetime 5369 5377	11/08/21
T541	Symptom 5353 5361	vomiting
A188	NegationModalityVal T541 affirmed
A189	IsPresentOnFirstCancerDiagnosis T541 no
A190	IsCausedByDiagnosedCancer T541 no
A191	ChronicVal T541 non-chronic
A192	ContinuityVal T541 stopped
R60	HappensAtOnDuring Arg1:T540 Arg2:T541	
T542	MedicationRegimen 5323 5331	Gem/Cape
A193	TreatmentContinuityVal T542 continuing
A194	TreatmentTypeVal T542 maintenance
A195	TreatmentIntentVal T542 palliative
T543	Cycles 5318 5322	C4D1
R61	TreatmentDesc Therapy:T543 Desc:T542	
R62	HappensAtOnDuring Arg1:T539 Arg2:T542	
R63	ConditionOrTreatmentCausesProblem Treatment:T542 Prob:T541	
T544	Symptom 5383 5394	hematemesis
A196	NegationModalityVal T544 negated
T545	Datetime 5398 5409	November 22
T546	ProcedureName 5410 5417;5430 5435	changed stent
A197	IntentVal T546 others
A198	TreatmentTypeVal T546 others
A199	TreatmentCategory T546 Others
T547	Site 5422 5429	jejunal
R64	SiteOf Arg1:T547 Arg2:T546	
R65	HappensAtOnDuring Arg1:T545 Arg2:T546	
T548	Datetime 5439 5447	11/10/21
T549	Cycles 5448 5453	C6D15
R66	TreatmentDesc Therapy:T549 Desc:T542	
R67	HappensAtOnDuring Arg1:T548 Arg2:T549	
T550	Datetime 5466 5474	12/02/21
T551	RadiationTherapyName 5477 5480	XRT
A200	TreatmentContinuityVal T551 finished
A201	TreatmentTypeVal T551 local
A202	TreatmentIntentVal T551 palliative
T552	Datetime 5482 5490	12/08/21
T553	Datetime 5494 5502	12/22/21
R68	BeginsOnOrAt Arg1:T551 Arg2:T552	
R69	EndsOnOrAt Arg1:T551 Arg2:T553	
T554	Datetime 5504 5512	12/22/21
T555	Radiology 5550 5557	CT scan
A203	NegationModalityVal T555 hypothetical_in_future
A204	IntentVal T555 others
A205	TreatmentContinuityVal T139 unclear
A206	TreatmentTypeVal T139 others
A207	TreatmentIntentVal T139 others
T556	TreatmentType 5770 5773	abx
A208	TreatmentContinuityVal T556 unclear
A209	TreatmentTypeVal T556 others
A210	TreatmentIntentVal T556 others
T557	Datetime 5619 5627	12/23/21
T558	Datetime 5713 5721	12/20/21
T559	Datetime 5742 5750	12/22/21
R70	BeginsOnOrAt Arg1:T139 Arg2:T557	
A211	IsPresentOnFirstCancerDiagnosis T140 no
A212	IsCausedByDiagnosedCancer T140 no
A213	ChronicVal T140 non-chronic
A214	ContinuityVal T140 stopped
R71	HappensAtOnDuring Arg1:T140 Arg2:T558	
R72	BeginsOnOrAt Arg1:T559 Arg2:T556	
A215	ChronicVal T144 non-chronic
A216	ContinuityVal T144 stopped
T560	Datetime 5957 5961	2017
T561	Datetime 6082 6094	October 2020
T562	Datetime 6146 6150	2000
T563	Datetime 6204 6208	2018
A138	ChronicVal T520 chronic
A139	ContinuityVal T520 stable
T564	ClinicalCondition 6257 6266	Psoriasis
A217	ChronicVal T564 chronic
A218	ContinuityVal T564 stable
T565	ClinicalCondition 6155 6167	Hearing loss
A219	ChronicVal T565 chronic
A220	ContinuityVal T565 stable
R73	HappensAtOnDuring Arg1:T144 Arg2:T560	
R74	HappensAtOnDuring Arg1:T516 Arg2:T561	
R75	HappensAtOnDuring Arg1:T517 Arg2:T562	
R76	HappensAtOnDuring Arg1:T519 Arg2:T563	
A221	IntentVal T154 others
A222	TreatmentTypeVal T154 others
A223	TreatmentCategory T154 Others
T566	ProcedureName 6347 6364	IR PORT PLACEMENT
A224	IntentVal T566 others
A225	TreatmentTypeVal T566 others
A226	TreatmentCategory T566 Others
T567	ProcedureName 6422 6439	IR PORT PLACEMENT
A227	IntentVal T567 others
A228	TreatmentTypeVal T567 others
A229	TreatmentCategory T567 Others
T568	TreatmentType 6529 6552	prostate cancer surgery
A230	TreatmentTypeVal T568 local
A231	TreatmentIntentVal T568 unclear
T569	Datetime 6408 6418	06/01/2021
T570	Datetime 6482 6492	06/01/2021
R77	HappensAtOnDuring Arg1:T567 Arg2:T570	
R78	HappensAtOnDuring Arg1:T566 Arg2:T569	
A232	NegationModalityVal T184 affirmed
A233	ChronicVal T184 chronic
A234	ContinuityVal T184 unclear
A235	ExperiencerVal T184 family
A236	NegationModalityVal T185 affirmed
A237	ChronicVal T185 chronic
A238	ContinuityVal T185 unclear
A239	ExperiencerVal T185 family
A240	NegationModalityVal T186 affirmed
A241	ChronicVal T186 chronic
A242	ContinuityVal T186 unclear
A243	ExperiencerVal T186 family
T571	ClinicalCondition 8815 8827	Hearing loss
A244	NegationModalityVal T571 affirmed
A245	ChronicVal T571 chronic
A246	ContinuityVal T571 unclear
A247	ExperiencerVal T571 family
T572	ClinicalCondition 8841 8853	Hearing loss
A248	NegationModalityVal T572 affirmed
A249	ChronicVal T572 chronic
A250	ContinuityVal T572 unclear
A251	ExperiencerVal T572 family
T573	ClinicalCondition 8867 8879	Hearing loss
A252	NegationModalityVal T573 affirmed
A253	ChronicVal T573 chronic
A254	ContinuityVal T573 unclear
A255	ExperiencerVal T573 family
T574	ClinicalCondition 8894 8912	Pulmonary fibrosis
A256	NegationModalityVal T574 affirmed
A257	ChronicVal T574 chronic
A258	ContinuityVal T574 unclear
A259	ExperiencerVal T574 family
T575	ClinicalCondition 8939 8967	hereditary pattern of cancer
A260	NegationModalityVal T575 negated
A261	ChronicVal T575 chronic
A262	ContinuityVal T575 unclear
A263	ExperiencerVal T575 family
T576	Tobacco 9071 9084	Former Smoker
A264	NegationModalityVal T576 affirmed
A265	IsStoppedOrContinuing T576 stopped
A266	ExperiencerVal T576 patient
T577	ConsumptionQuantity 9100 9104	0.50
R79	ConsumptionQuantityRel Arg1:T577 Arg2:T576	
T578	Duration 9116 9121	28.00
R80	Temporal Arg1:T578 Arg2:T576	
T579	ConsumptionQuantity 9138 9143	14.00
R81	ConsumptionQuantityRel Arg1:T579 Arg2:T576	
T580	Datetime 9182 9186	1990
T581	Datetime 9202 9206	2008
R82	BeginsOnOrAt Arg1:T576 Arg2:T580	
R83	EndsOnOrAt Arg1:T576 Arg2:T581	
T582	Alcohol 9321 9326	Never
A268	NegationModalityVal T582 negated
T583	Alcohol 9341 9346	Never
A269	NegationModalityVal T583 negated
T584	Alcohol 9368 9381	Not Currently
A270	NegationModalityVal T584 negated
T585	Datetime 9437 9441	2021
T586	Employment 9453 9469	work in business
A272	NegationModalityVal T586 affirmed
A273	IsStoppedOrContinuing T586 stopped
T587	Age 18677 18679	78
T588	ClinicalCondition 18705 18730	pancreatic adenocarcinoma
A274	ChronicVal T588 chronic
A275	ContinuityVal T588 stable
T589	ClinicalCondition 18766 18769	SBO
A276	ChronicVal T589 non-chronic
A277	ContinuityVal T589 stopped
T590	ProcedureName 18774 18782	stenting
A278	IntentVal T590 others
A279	TreatmentTypeVal T590 others
A280	TreatmentCategory T590 Others
R84	TestOrProcedureConductedForProblem Test:T590 Prob:T589	
T591	ClinicalCondition 18787 18812	Pancreatic Adenocarcinoma
A281	ChronicVal T591 chronic
A282	ContinuityVal T591 stable
T592	MedicationRegimen 18832 18840	Gem Cape
A283	TreatmentContinuityVal T592 continuing
A284	TreatmentTypeVal T592 maintenance
A285	TreatmentIntentVal T592 palliative
T593	Cycles 18820 18821	6
R85	TreatmentDesc Therapy:T593 Desc:T592	
T594	RadiationTherapyName 18861 18864	XRT
A286	TreatmentContinuityVal T594 planned
A287	TreatmentTypeVal T594 local
A288	TreatmentIntentVal T594 palliative
T595	TreatmentType 18894 18910	systemic therapy
A289	TreatmentContinuityVal T595 continuing
A290	TreatmentTypeVal T595 maintenance
A291	TreatmentIntentVal T595 palliative
T596	TreatmentType 18924 18933	radiation
A292	TreatmentContinuityVal T596 planned
A293	TreatmentTypeVal T596 local
A294	TreatmentIntentVal T596 palliative
T597	DiagnosticLabTest 18991 18998	CA 19-9
A295	IntentVal T597 TreatmentAssessment
T598	LabTestResult 18974 18990	does not express
A296	LabTestResultVal T598 normal
R86	ResultOfTest Desc:T598 Test:T597	
T599	Symptom 19005 19008	GIB
A297	IsPresentOnFirstCancerDiagnosis T599 no
A298	IsCausedByDiagnosedCancer T599 yes
A299	ChronicVal T599 non-chronic
A300	ContinuityVal T599 improving
T600	DiagnosticLabTest 19086 19089	CBC
A301	NegationModalityVal T600 planned_in_future
T601	Frequency 19079 19085	weekly
R87	Temporal Arg1:T601 Arg2:T600	
R88	TestOrProcedureConductedForProblem Test:T600 Prob:T599	
T602	TreatmentType 19094 19109	transfuse PRBCs
A302	NegationModalityVal T602 hypothetical_in_future
A303	TreatmentTypeVal T602 others
A304	TreatmentIntentVal T602 others
R89	TreatmentAdministeredForProblem Treatment:T602 Prob:T599	
T603	DiagnosticLabTest 19118 19121	HGB
A305	NegationModalityVal T603 hypothetical_in_future
T604	LabTestResult 19122 19126	<8.0
A306	LabTestResultVal T604 abnormal
A307	NegationModalityVal T604 hypothetical_in_future
R90	ResultOfTest Desc:T604 Test:T603	
T605	ClinicalCondition 19136 19160	biliary duct obstruction
A308	ChronicVal T605 non-chronic
A309	ContinuityVal T605 stopped
T606	ProcedureName 19168 19197	biliary metal stent placement
A310	IntentVal T606 others
A312	TreatmentCategory T606 Supportive
R91	TestOrProcedureConductedForProblem Test:T606 Prob:T605	
T607	Datetime 19198 19206	05/06/21
R92	HappensAtOnDuring Arg1:T607 Arg2:T606	
T608	DiagnosticLabTest 19230 19241	alk p/t bil
A311	IntentVal T608 others
A313	NegationModalityVal T608 planned_in_future
T609	ClinicalCondition 19250 19273	small bowel obstruction
A314	ChronicVal T609 non-chronic
A315	ContinuityVal T609 stopped
T610	ProcedureName 19306 19309	EGD
A316	IntentVal T610 others
A317	TreatmentTypeVal T610 others
A318	TreatmentCategory T610 Others
R93	TestOrProcedureConductedForProblem Test:T610 Prob:T609	
T611	ProcedureName 19314 19341	placement of duodenal stent
A319	IntentVal T611 others
A320	TreatmentTypeVal T611 others
A321	TreatmentCategory T611 Others
T612	Datetime 19342 19350	05/06/21
R94	HappensAtOnDuring Arg1:T612 Arg2:T611	
R95	HappensAtOnDuring Arg1:T612 Arg2:T610	
T613	ClinicalCondition 19402 19408	C Diff
A322	ChronicVal T613 non-chronic
A323	ContinuityVal T613 stopped
A324	ExperiencerVal T613 patient
T614	Symptom 19444 19452	abd pain
A325	IsPresentOnFirstCancerDiagnosis T614 no
A326	IsCausedByDiagnosedCancer T614 unclear
A327	ChronicVal T614 non-chronic
A328	ContinuityVal T614 unclear
T615	MedicationName 19464 19469	Creon
A329	TreatmentContinuityVal T615 continuing
A330	TreatmentTypeVal T615 others
A331	TreatmentIntentVal T615 others
A332	TreatmentCategory T615 Supportive
R96	TreatmentAdministeredForProblem Treatment:T615 Prob:T614	
T616	ClinicalCondition 19473 19486	Aspergillosis
A333	ChronicVal T616 chronic
A334	ContinuityVal T616 stable
A335	IntentVal T398 others
A336	TreatmentTypeVal T398 others
A337	TreatmentCategory T398 Others
R97	TestOrProcedureConductedForProblem Test:T398 Prob:T616	
T617	DiagnosticLabTest 19689 19697	cultures
A338	IntentVal T617 others
R98	TestOrProcedureConductedForProblem Test:T617 Prob:T616	
T618	Datetime 19664 19672	February
R99	HappensAtOnDuring Arg1:T398 Arg2:T618	
A339	NegationModalityVal T398 planned_in_future
A340	NegationModalityVal T617 planned_in_future
T619	Datetime 19755 19766	February 17
T620	ClinicalCondition 19773 19801	protein calorie malnutrition
A341	ContinuityVal T620 stable
T621	ClinicalCondition 20039 20047	Insomnia
A342	ContinuityVal T621 stable
T622	Datetime 19715 19727	next Tuesday
A343	ContinuityVal T622 stable
T623	Symptom 19900 19904	Pain
A344	NegationModalityVal T623 negated
T624	MedicationName 19994 19999	Norco
A345	TreatmentContinuityVal T624 continuing
A346	TreatmentTypeVal T624 others
A347	TreatmentIntentVal T624 others
A348	TreatmentCategory T624 Supportive
R100	TreatmentAdministeredForProblem Treatment:T624 Prob:T623	
A349	TreatmentContinuityVal T405 continuing
A350	TreatmentTypeVal T405 others
A351	TreatmentIntentVal T405 others
A352	TreatmentCategory T405 Supportive
A353	TreatmentContinuityVal T406 continuing
A354	TreatmentTypeVal T406 others
A355	TreatmentIntentVal T406 others
A356	TreatmentCategory T406 Supportive
R101	TreatmentAdministeredForProblem Treatment:T405 Prob:T621	
R102	TreatmentAdministeredForProblem Treatment:T406 Prob:T621	
T625	Symptom 20235 20248	pain symptoms
A357	NegationModalityVal T625 negated
T626	Datetime 20209 20217	01/31/22
T627	TreatmentType 6559 6575	PROSTATE SURGERY
A358	TreatmentTypeVal T627 local
A359	TreatmentIntentVal T627 unclear
T628	SectionSkip 6584 6631	Allergies/Contraindications  No Known Allergies
A360	SectionSkipType T628 allergies
T629	SectionSkip 6636 7874;7877 8650	Current Outpatient Medications   Medication Instructions    acetaminophen (TYLENOL) 325 mg, Oral, Once PRN    bisacodyL (DULCOLAX) 5 mg, Oral, Once PRN    budesonide-glycopyr-formoterol (BREZTRI AEROSPHERE) 160-9-4.8 mcg/actuation INH 2 puffs, Inhalation, 2 times daily    calcium carbonate-vitamin D (OSCAL D) 1,250 mg (500 mg elemental)-200 unit tablet 1 Tbsp, Oral, Every 4 Hours PRN    CALCIUM CITRATE ORAL 1 tablet, Oral, Daily Scheduled    capecitabine (XELODA) 500 mg tablet Take 3 tabs (1500 mg) in the morning with food, take 2 tabs (1000 mg) in the evening with food. Take for 7 days, and then do not take for 7 days.    CREON 6,000-19,000 -30,000 unit capsule TAKE 1 CAPSULE BY MOUTH 3 TIMES DAILY WITH MEALS.    denosumab (PROLIA) 60 mg, Subcutaneous, See Admin Instructions, Inject 60 mg subcutaneously as directed*****Clinic administered every 6 mos    dronabinoL (MARINOL) 2.5 mg, Oral, 2 Times Daily Before Meals Scheduled, Take 1 hour before breakfast and one hour before dinner.    famotidine (PEPCID ORAL) Oral    GLIMEPIRIDE ORAL 5 mg, Oral, Daily At Bedtime Scheduled    lipase-protease-amylase (CREON) 6,000-19,000 -30,000 unit capsule TAKE 1 CAPSULE BY MOUTH 3 TIMES DAILY WITH MEALS.    melatonin 1 mg tablet Oral, Daily At Bedtime Scheduled    mirtazapine (REMERON) 15 mg tablet TAKE 1 TABLET BY MOUTH EVERYDAY AT BEDTIME    multivitamin tablet 1 tablet, Oral, Daily Scheduled, Brand:  Centrum    ondansetron (ZOFRAN) 8 mg, Oral, Every 8 Hours PRN    pantoprazole (PROTONIX) 40 mg EC tablet Take Pantoprazole 40 ***** tablets, twice daily. Pantoprazole 40 mg tablet 30 minutes before your first meal of the day and 30 minutes before bedtime.    pantoprazole (PROTONIX) 40 mg, Oral, 2 times daily    polyethylene glycol (MIRALAX) 17 g, Oral, Daily Scheduled    prochlorperazine (COMPAZINE) 10 mg, Oral, Every 6 Hours PRN    senna (SENOKOT) 17.2 mg, Oral, Daily At Bedtime Scheduled    sucralfate (CARAFATE) 1 g, Oral, 4 Times Daily Before Meals and Bedtime Scheduled
A361	SectionSkipType T629 medications
T630	SectionSkip 9496 9829;9832 9951	Vitals    Flowsheet Row Most Recent Value   Pain Score 0          Wt Readings from Last 3 Encounters:   12/22/21 54 kg (119 lb)   11/29/21 55.3 kg (122 lb)   11/28/21 55.6 kg (122 lb 9.6 oz)      ECOG performance status 2 - Symptomatic, <50% confined to bed  Gen NAD  Able to ambulate in the room without assistance   Respiratory: No respiratory distress, no cough, no use of accessory muscles   LE: No edema  Psych:  appropriate A&O X 3  Neck: full ROM
A362	SectionSkipType T630 physical_exam
T631	SectionSkip 11232 11795;11798 13738;13741 15694;15697 17645;17648 17856	CLINICAL HISTORY: Pancreatic adenocarcinoma Restaging scans. COMPARISON:  CT abdomen pelvis 11/18/2021 TECHNIQUE: CT of the abdomen and pelvis was performed. MEDICATIONS: Iohexol 350 - 100 mL - Intravenous FINDINGS: Visualized lung bases:  For chest findings, please see the separately dictated report from the CT of the chest of the same date. Liver:  Persistent mild intrahepatic and extrahepatic biliary dilation with decreased pneumobilia. Similar position of common bile duct stent. Gallbladder: Prior cholecystectomy. Similar fluid in the gallbladder fossa. Spleen:  Unremarkable Pancreas:  Similar size of ill-defined pancreatic mass in the uncinate process, measuring approximately 5.2 x 2.0 cm (series 5, image 72) compared to 5.2 x 2.2 cm on 11/18/2021. Adrenal Glands:  Unremarkable Kidneys:  Contrast in the bilateral collecting systems and ureters. Benign cyst in the right kidney lower pole. GI Tract:  Persistent encasement of the third portion of the duodenum by the pancreatic mass. Similar enhancing soft tissue within the stent, suspicious for tumor (series 5, image 76). Unchanged position of duodenal stent. Interval gastrojejunostomy with axios stent in place. Nondistended stomach. Diverticulosis without findings of acute diverticulitis. Vasculature:  Moderate atherosclerotic disease of the abdominal aorta and its branches. Unchanged obliteration of the superior mesenteric vein at the level of the pancreatic mass. The mass demonstrate similar abutment of the distal superior mesenteric artery. Lymphadenopathy: Similar mesenteric lymph nodes adjacent to the mass, the largest measuring 1.0 cm (series 5, image 68). Peritoneum: No ascites Bladder: Contrast layering dependently in the bladder. Reproductive organs: Unremarkable Bones:  No suspicious lesions Extraperitoneal soft tissues: Similar medium fat-containing left inguinal hernia. Lines/drains/medical devices: As above. RADIATION DOSE INDICATORS: Exposure Events: 3 , CTDIvol Min: 6.8 mGy, CTDIvol Max: 6.8 mGy, DLP: 449.1 mGy.cm. The following accession numbers are related to this dose report *****,*****     1.  Similar size of pancreatic mass centered in the uncinate process and invading the duodenum. Similar peripancreatic lymph nodes. 2.  Interval placement of gastrojejunal stent. No findings of proximal obstruction.     CT Chest with Contrast    Result Date: 01/31/2022  CT CHEST WITH CONTRAST CLINICAL HISTORY:  Initial staging COMPARISON: CT chest dated 01/05/2022. TECHNIQUE: Serial 1.25 mm axial images through the chest were obtained after the administration of intravenous contrast. Iohexol 350 - 100 mL - Intravenous RADIATION DOSE INDICATORS: Exposure Events: 3 , CTDIvol Min: 6.8 mGy, CTDIvol Max: 6.8 mGy, DLP: 449.1 mGy.cm FINDINGS: Right chest wall port with tip terminating in the superior cavoatrial junction. LUNGS: Overall, slight improvement in waxing and waning multifocal peribronchovascular groundglass, now worse in the right upper lobe and improved in the left upper lobe. Bronchial wall thickening, most notably within the right lower lobe. PLEURA: No pleural effusion or pneumothorax. MEDIASTINUM: Unchanged mediastinal lymph nodes. HEART/GREAT VESSELS: The heart is normal in size without evidence of pericardial effusion. Severe coronary artery atherosclerotic calcifications. Normal caliber thoracic aorta and main pulmonary artery. BONES/SOFT TISSUES: No suspicious osseous lesions. VISIBLE ABDOMEN: Please see dedicated Abdomen and Pelvis CT report.     1.  Slight improvement in waxing and waning multifocal peribronchovascular groundglass, compatible with an organizing pneumonia pattern of lung injury, which may be secondary to infection or drug reaction. No new or enlarging solid pulmonary nodules. 2. Persistent bronchial wall thickening of the lower lobes, possibly secondary to airway spread of infection. Report dictated by: ***** ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging    CT Chest with Contrast    Result Date: 01/05/2022  CT CHEST WITH CONTRAST CLINICAL HISTORY:  Pancreatic adenocarcinoma hx latent tB, fevers COMPARISON: Thoracic CT from 11/18/2021 and more remote priors TECHNIQUE: Serial 1.25 mm axial images through the chest were obtained after the administration of intravenous contrast. Iohexol 350 - 100 mL - Intravenous RADIATION DOSE INDICATORS: Exposure Events: 3 , CTDIvol Max: 4 mGy, DLP: 158.9 mGy.cm FINDINGS: SUPPORT DEVICE(S): Right chest port catheter terminates at the superior cavoatrial junction. LUNGS: Increased upper lobe predominant peribronchovascular groundglass/perilobular opacities. Increased atelectasis in the right middle lobe and lingula. New nodular consolidation in the left lower lobe (series 301, image 364). PLEURA: No pleural effusion. MEDIASTINUM: A few mediastinal nodes have increased in size. For reference, an AP window node measures 0.6 cm in short axis, previously 0.4 cm (series 2, image 96). These are probably reactive to regional inflammation. Mild diffuse esophageal wall thickening, nonspecific. HEART/GREAT VESSELS: Normal heart size. No pericardial effusion. Mild coronary artery calcifications. BONES/SOFT TISSUES: No suspicious lesion. VISIBLE ABDOMEN: Increased pneumobilia with intrahepatic and extra hepatic biliary ductal dilation. Thickened, enhancing walls of the hepatic, cystic, and upper common bile ducts, similar to prior exam. Partially imaged common bile duct stent. Several small vessels course along the gastric wall, as seen previously. Partially imaged gastrostomy stent communicating with a left upper quadrant bowel loop. Partially imaged stent within the more posterior lateral aspect of this same bowel loop. Mildly enlarged enhancing node adjacent to the central mesenteric vascular pedicle measuring 1.0 cm in short axis (series 2, image 258). Mild adjacent haziness of the central mesenteric vascular pedicle. Otherwise unremarkable.     1.  Compared 11/18/2021, increased bilateral upper lobe predominant pulmonary opacities compatible with organizing pneumonia pattern lung injury. Considerations include viral infection and/or medication-induced pulmonary injury. 2.  Background of clustered nodules and nodular consolidation compatible with chronic airway infection. 3.  No definite evidence of thoracic metastatic disease. 4.  Increased pneumobilia and biliary ductal dilation. Correlate with laboratory evidence of biliary obstruction if indicated. Report dictated by: ***** *****, MD, signed by: ***** *****, MD Department of Radiology and Biomedical Imaging      I reviewed CT with the patient  I interpret this as stable disease
A363	SectionSkipType T631 radiology_report
T632	Datetime 89 99	04/05/1943
T633	Datetime 149 159	01/31/2022
R103	TumorDesc TumorDetails:T505 Desc:T506	
R104	HappensAfter Arg1:T550 Arg2:T555	
T2	Duration 9233 9237	14.8
R105	HappensBefore Arg1:T576 Arg2:T2	
T634	Frequency 19110 19113	PRN
R106	Temporal Arg1:T602 Arg2:T634	
T635	SDoH 9412 9422	Immigrated
R107	HappensAtOnDuring Arg1:T635 Arg2:T585	
R108	TreatmentAdministeredForProblem Treatment:T452 Prob:T420	
R109	ExclusionCriteriaFor Arg1:T453 Arg2:T452	
R110	SiteOf Arg1:T460 Arg2:T459	
R111	SiteOf Arg1:T461 Arg2:T459	
R112	ConditionOrTreatmentCausesProblem Treatment:T459 Prob:T463	
R113	ConditionOrTreatmentCausesProblem Treatment:T459 Prob:T462	
R114	TestOrProcedureReveals Test:T465 Desc:T66	
R115	ExclusionCriteriaFor Arg1:T473 Arg2:T472	
A364	NegationModalityVal T107 hypothetical_in_future
A365	TreatmentIntentVal T107 palliative
A366	TreatmentTypeVal T107 maintenance
A367	NegationModalityVal T108 hypothetical_in_future
A368	TreatmentTypeVal T108 maintenance
A369	TreatmentIntentVal T108 palliative
A370	NegationModalityVal T109 hypothetical_in_future
A371	TreatmentTypeVal T109 local
A372	TreatmentIntentVal T109 palliative
R116	HappensAtOnDuring Arg1:T509 Arg2:T511	
A373	TreatmentIntentVal T401 others
A374	TreatmentIntentVal T408 others
T636	hpi_start 56 63	Patient
T637	hpi_end 2338 2343	pain.
T638	hpi_start 3354 3356	06
T3	hpi_end 5797 5804	helped.
T639	ap_start 18622 18632	Assessment
T640	ap_end 20240 20248	symptoms
R117	HappensAtOnDuring Arg1:T470 Arg2:T471	
R118	HappensAtOnDuring Arg1:T510 Arg2:T509	
